REG - GENinCode PLC - Result of Retail Offer

GenincodeAnnouncement

18/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250218:nRSR4258Xa&default-theme=true

RNS Number : 4258X  GENinCode PLC  18 February 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW
PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON
LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE,
PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO
THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN.

 

18 February 2025

 

GENINCODE PLC

("GENinCode" or the "Company") (AIM: GENI.L)

 

Result of Retail Offer

 

GENinCode plc (AIM: GENI.L), a genetics company focused on the prevention of
cardiovascular disease ("CVD") and the early detection of ovarian cancer,
announced on 14 February 2025 the launch of a fundraising comprising a
Placing and Subscription to raise a minimum of £4.0 million. The Company also
announced on 14 February 2025 that it intended to carry out a separate Retail
Offer via RetailBook  (the "Retail Offer"  together with the Placing and
Subscription, being the "Fundraising"). The Company announced on 14 February
2025 that it had conditionally raised £4 million through the Placing and
Subscription.

The Company confirms that the Retail Offer closed at 5.00 p.m. on 17 February
2025 and that it has received conditional subscriptions for 1,809,508 new
Ordinary Shares at the Issue Price of 3.7 pence per share in the Retail Offer.

Following the close of the Retail Offer, the Company has conditionally raised
gross proceeds of approximately £4.1 million at the Issue Price via the
Fundraising. The Company will therefore allot and issue an aggregate of
109,917,616 New Ordinary Shares in connection with the Fundraising.

Each of the Retail Offer, the Placing and the Subscription is conditional upon
the fundraising resolutions being duly passed without amendment at a General
Meeting of the Company to be held on 3 March 2025 and Admission becoming
effective at 8:00 am on or around 4 March 2025 (or such later date as the
Company and its advisors may agree, but not later than 31 March 2025).

Capitalised terms used in this announcement shall, unless defined in this
announcement or unless the context provides otherwise, bear the same meaning
ascribed to such terms in the launch announcement.

Admission and Total Voting Rights

Application will be made to the London Stock Exchange for 109,917,616 New
Ordinary Shares (comprising 88,040,541 Placing Shares, 20,067,567 Subscription
Shares and 1,809,508 Retail Shares) to be admitted to trading on AIM.
Admission is expected to take place and dealings in the New Ordinary Shares
are expected to commence at 8.00 a.m. on or around 4 March 2025, at which time
it is also expected that the New Ordinary Shares will be enabled for
settlement in CREST.

Immediately following Admission, the issued share capital of the Company is
expected to comprise 286,882,042 Ordinary Shares. Each Ordinary Share has one
voting right and no Ordinary Shares are held in treasury. Accordingly,
immediately following Admission, the total number of voting rights in the
Company will be 286,882,042. From Admission, this figure may be used by
Shareholders as the denominator for the calculation by which they will
determine if they are required to notify their interest in, or a change to
their interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

Enquiries:

 GENinCode Plc                                        or via Walbrook PR
 Matthew Walls, CEO

 Paul Foulger, CFO

 RetailBook Limited                                  capitalmarkets@retailbook.com (mailto:capitalmarkets@retailbook.com)

 Aaqib Mirza / Michael Ward

 Walbrook PR Limited                                 Tel: 020 7933 8780 or
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage  genincode@walbrookpr.com (mailto:genincode@walbrookpr.com)

 

Notes:

References to times in this Announcement are to London time unless otherwise
stated.

The times and dates mentioned throughout this Announcement may be adjusted by
the Company in which event the Company will make an appropriate announcement
to a Regulatory Information Service giving details of any revised dates and
the details of the new times and dates will be notified to London Stock
Exchange plc (the "London Stock Exchange") and, where appropriate,
Shareholders. Shareholders may not receive any further written communication.

IMPORTANT INFORMATION

This Announcement is not for publication or distribution, directly or
indirectly, in or into the United States of America. This Announcement is not
an offer of securities for sale into the United States. The securities
referred to herein have not been and will not be registered under the U.S.
Securities Act of 1933, as amended, and may not be offered or sold in the
United States, except pursuant to an applicable exemption from registration.
No public offering of securities is being made in the United States.

This Announcement and the information contained herein, is restricted and is
not for publication, release or distribution, directly or indirectly, in whole
or in part, in or into Australia, Canada, the Republic of South Africa, Japan
or any other jurisdiction in which such publication, release or distribution
would be unlawful.  Further, this Announcement is for information purposes
only and is not an offer of securities in any jurisdiction.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIKDLFFELLBBBK